{
    "clinical_study": {
        "@rank": "110815", 
        "biospec_descr": {
            "textblock": "Human plasma"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "All subjects in this study have previously been in an Idenix HCV study and received study\n      drug for 3 consecutive days.  Subjects who had received placebo in a previous Idenix study\n      will not be enrolled in this study.\n\n      In this study, researchers will try to find answers to these questions:\n\n        -  How much (if any) hepatitis C virus is in your blood after stopping your Idenix study\n           drug?\n\n        -  Is your hepatitis C virus possibly resistant to treatment with the Idenix study drug or\n           similar drugs?"
        }, 
        "brief_title": "3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "detailed_description": {
            "textblock": "The data obtained from this study will be used to further understand the long-term efficacy\n      of Idenix DAAs used to treat HCV infection and to further understand HCV resistance to\n      Idenix DAAs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Read and signed the written informed consent form (ICF) after the nature of the study\n             has been fully explained\n\n          -  Have participated in an Idenix-sponsored study of an Idenix DAA\n\n          -  Received at least 3 consecutive days of DAA treatment in an Idenix-sponsored study\n\n          -  Agreed to comply with the visit schedule and laboratory tests\n\n        Exclusion Criteria:\n\n          -  Treatment with placebo only, in an Idenix sponsored study\n\n          -  Antiviral treatment for HCV after participation in an Idenix sponsored study of an\n             Idenix DAA"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The population will include subjects who participated in studies of Idenix anti-HCV DAAs."
            }
        }, 
        "enrollment": {
            "#text": "183", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721265", 
            "org_study_id": "IDX-03YF"
        }, 
        "intervention_browse": {
            "mesh_term": "Antiviral Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HCV", 
            "Hepatitis C", 
            "IDX184", 
            "IDX719"
        ], 
        "lastchanged_date": "May 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66212"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "3-Year, Observational Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals", 
        "overall_contact": {
            "email": "Sullivan-Bolyai.John@idenix.com", 
            "last_name": "John Z Sullivan-Bolyai, MD, MPH", 
            "phone": "1877-433-6491"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the durability of sustained virological response (SVR).  Plasma HCV RNA levels will be monitored over time.", 
            "measure": "Durability of Sustained viral response [SVR]", 
            "safety_issue": "No", 
            "time_frame": "every 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721265"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To describe the kinetics of resistant variants to Idenix direct acting antivirals (DAAs) by HCV RNA sequencing.  The presence of each identified resistant variant in the viral population will be descriptively evaluated until the viral population consists entirely of wild-type virus or over a period of 3 years, whichever comes first.", 
            "measure": "Kinetics of resistant variants", 
            "safety_issue": "No", 
            "time_frame": "every 3 months"
        }, 
        "source": "Idenix Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Idenix Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}